Brief: Relief Therapeutics Announces IRB Approval Of Investigator-Initiated Trial Evaluating RLF-TD011
Jan 17 (Reuters) - Relief Therapeutics Holding SA
RLFB.S :
* RELIEF THERAPEUTICS ANNOUNCES IRB APPROVAL OF
INVESTIGATOR-INITIATED TRIAL EVALUATING RLF-TD011 AS AN
ADJUNCTIVE TREATMENT FOR CUTANEOUS T-CELL LYMPHOM
Source text for Eikon: ID:nEQXpJgja
Further company coverage: RLFB.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MindMaze Therapeutics Holding SA
See all newsBrief: Mindmaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
Brief: Relief Therapeutics Shareholders Approve Business Combination With Neurox
Brief: Relief Therapeutics Receives FDA Response To Qidp Request For Rlf-Td011
Brief: Relief Therapeutics Says Interim CEO Michelle Lock Has Completed Her Transitional Mandate
Swiss stocks - Factors to watch on May 13